Halozyme Therapeutics, Inc. · NASDAQ:HALO

Torley Helen sold 60,000 Halozyme Therapeutics, Inc. shares (Form 4)

Traded Oct 6 to Oct 8, 2026 · Filed Oct 8, 2026

From Oct 6 to Oct 8, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 60,000 Halozyme Therapeutics, Inc. shares at an average US$110.18 for US$6.61M under a trading plan, leaving 767,780 shares. Filed Oct 8, 2026 (Form 4).

Sold
60,000 shares
Price
US$110.18 average (US$107.90 to US$113.69)
Value
US$6.61M
Holding after
767,780 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director, PRESIDENT AND CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Oct 6, 2026Common StockOption exercise20,000US$18.41787,780Direct
Oct 6, 2026Common StockSale2,300US$107.90785,480Direct
Oct 6, 2026Common StockSale6,000US$109.33779,480Direct
Oct 6, 2026Common StockSale9,920US$109.89769,560Direct
Oct 6, 2026Common StockSale1,780US$110.81767,780Direct
Oct 7, 2026Common StockOption exercise20,000US$18.41787,780Direct
Oct 7, 2026Common StockSale8,600US$111.03779,180Direct
Oct 7, 2026Common StockSale10,300US$111.84768,880Direct
Oct 7, 2026Common StockSale900US$112.78767,980Direct
Oct 7, 2026Common StockSale200US$113.69767,780Direct
Oct 8, 2026Common StockOption exercise20,000US$18.41787,780Direct
Oct 8, 2026Common StockSale4,810US$108.18782,970Direct
Oct 8, 2026Common StockSale3,090US$108.91779,880Direct
Oct 8, 2026Common StockSale11,900US$110.00767,980Direct
Oct 8, 2026Common StockSale200US$110.51767,780Direct

Source

View original at SEC

Related